Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PRF TechnologiesPRFX -2.38%22 Quick Ratio is 5.07 as of Jun. 2026, which is 14% above its 10-year median of 4.44. GuruFocus rates PRFX with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 997 Drug Manufacturers companies, PRF Technologies ranks better than 89.17% on this metric.
PRF Technologies (NAS:PRFX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
PRF Technologies Quick Ratio Related Terms
PRF Technologies Quick Ratio Historical Data
* Premium members only.
The historical data trend for PRF Technologies's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PRF Technologies's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PRF Technologies Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PRF Technologies's Quick Ratio distribution charts can be found below:
* The bar in red indicates where PRF Technologies's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
PRF Technologies's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRF Technologies (PRFX) has a Quick Ratio of 5.07 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on PRF Technologies and its competitors. This is 14% above median its historical median of 4.44. Over the past decade, PRF Technologies' Quick Ratio has ranged from 0.08 to 32.32. According to the industry distribution chart, PRF Technologies ranks #108 out of 997 companies in the Drug Manufacturers industry, placing it in the top 10.8%.
Is PRF Technologies' Quick Ratio too high?
PRF Technologies' current Quick Ratio of 5.07 is 14% above median its 10-year median of 4.44. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 32.32. The Drug Manufacturers industry median Quick Ratio is 1.40. PRF Technologies' value of 5.07 is 262.1% above this industry median. Based on the distribution chart, PRF Technologies ranks #108 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PRF Technologies has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does PRF Technologies' Quick Ratio compare to CTTH and UPC?
According to the Drug Manufacturers industry distribution chart, PRF Technologies ranks #108 out of 997 companies for Quick Ratio. This places PRF Technologies in the top 11% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.40. PRF Technologies' value of 5.07 is 262.1% above this benchmark. Historically, PRF Technologies' own Quick Ratio has ranged from 0.08 to 32.32 over the past decade. While the company's 10-year median is 4.44 vs. the industry median of 1.40, PRF Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.40, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PRF Technologies's current Quick Ratio of 5.07 is 262.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on PRF Technologies and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PRF Technologies's current Quick Ratio is 5.07, which is 14% above median its own 10-year median of 4.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PRF Technologies stock overvalued right now?
PRF Technologies (PRFX) has a current Quick Ratio of 5.07. The current Quick Ratio is 5.07, which is 14% above median its 10-year median of 4.44 and 262.1% above the Drug Manufacturers industry median of 1.40. PRF Technologies' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For PRF Technologies (PRFX), the current Quick Ratio is 5.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
22GF Score
Get the complete analysis for PRFX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRFX has been successfully added to your 
